266 related articles for article (PubMed ID: 32112040)
21. Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Chen WF; Wu L; Du ZR; Chen L; Xu AL; Chen XH; Teng JJ; Wong MS
Phytomedicine; 2017 Feb; 25():93-99. PubMed ID: 28190476
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
23. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
24. The MPTP/probenecid model of progressive Parkinson's disease.
Carta AR; Carboni E; Spiga S
Methods Mol Biol; 2013; 964():295-308. PubMed ID: 23296790
[TBL] [Abstract][Full Text] [Related]
25. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Wang Y; Bouabid S; Darvas M; Zhou FM
Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
[TBL] [Abstract][Full Text] [Related]
26. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
28. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
29. Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Vaz RL; Sousa S; Chapela D; van der Linde HC; Willemsen R; Correia AD; Outeiro TF; Afonso ND
Pharmacol Biochem Behav; 2020 Feb; 189():172828. PubMed ID: 31785245
[TBL] [Abstract][Full Text] [Related]
30. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
32. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
33. Dopamine receptor D2 on CD4
Liu Z; Zhai XR; Du ZS; Xu FF; Huang Y; Wang XQ; Qiu YH; Peng YP
Brain Behav Immun; 2021 Nov; 98():110-121. PubMed ID: 34403737
[TBL] [Abstract][Full Text] [Related]
34. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
[TBL] [Abstract][Full Text] [Related]
36. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
37. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
39. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
